

# Integrating drug eluting balloon into regular pci practice – our experience in Singapore

Dr Paul Ong  
Head of Interventional Services  
Tan Tock Seng Hospital  
National Healthcare Group, Singapore



Tan Tock Seng  
HOSPITAL

*Caring  
for  
you  
since*  
**1844**



# Outline

- **Current indications**
- **Registry**
  - Clinical characteristics**
  - Clinical outcomes**
  - Case highlights**

## Guidelines on myocardial revascularization

### The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)

Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI)<sup>‡</sup>

**Table 33** Recommendations for specific percut

FFR-guided PCI is recommended for detection of ischaemia-related ischaemia is not available.	I	A	15, 28
DES <sup>d</sup> are recommended for reduction of restenosis/re-occlusion, if no contraindication to extended DAPT.	I	A	45, 46, 55, 215
Distal embolic protection is recommended during PCI of SVG disease to avoid distal embolization of debris and prevent MI.	I	B	171, 213
Rotablation is recommended for preparation of heavily calcified or severely fibrotic lesions that cannot be crossed by a balloon or adequately dilated before planned stenting.	I	C	—
Manual catheter thrombus aspiration should be considered during PCI of the culprit lesion in STEMI.	IIa	A	204–208
For PCI of unstable lesions, i.v. abciximab should be considered for pharmacological treatment of no-reflow.	IIa	B	55, 209, 212


**Drug-eluting balloons<sup>d</sup> should be considered for the treatment of in-stent restenosis after prior BMS.**

**IIa B**

Proximal embolic protection may be considered for preparation before PCI of SVG disease.	IIb	B	214
For PCI of unstable lesions, intracoronary or i.v. adenosine may be considered for pharmacological treatment of no-reflow.	IIb	B	209
Tornus catheter may be used for preparation of heavily calcified or severely fibrotic lesions that cannot be crossed by a balloon or adequately dilated before planned stenting.	IIb	C	—
Cutting or scoring balloons may be considered for dilatation of in-stent restenosis, to avoid slipping-induced vessel trauma of adjacent segments.	IIb	C	—

# Current Indications for DEB

- Bare metal ISR
- DES ISR
- Small vessel disease



# Conditions where DEB maybe useful in the real world

- **Patients who will benefit from shortened duration of DAPT e.g those with increased bleeding risk, who require long term anti-coagulation, requires early surgery, non-compliant to medications, etc.**
- **Specific situations in which stent implantation is to be avoided.**

# Important Principles

## Use of DEB in PCI

**DEB-only**  
**(preferred approach)**

**DEB + BMS**

\*\* Predilate lesion before treating with DEB


\*\* Length of DEB > BMS

**\*\* ADEQUATE LESION PREPARATION**  
**( Scoreflex/Angiosculpt)**

**DAPT: 4 weeks**

**DAPT : 6 months**

# Angioplasty Trends in TTSH (Year 2008 to 2012)






# SeQuent Please DEB

Paccocath  
Technology




Combines targeted drug  
delivery with PTCA  
balloon

Balloon surface  
in contact with  
vessel wall



30s balloon inflation for  
effective drug delivery to  
vessel wall

Paclitaxel migrates  
into vessel wall



Paclitaxel migrates into  
SMC to prevent  
proliferation

# TTSH SeQuent Please Registry

Study Period	Jan 2010 to	Dec 2012
Number of patients	339	
Number of lesions	356	
Gender M:F	76:24	
Mean age	<b>61.5 ± 11 yrs</b>	

Clinical Presentation	N	(%)
STEMI	51	(15)
NSTEMI / UAP	203	(60)
Angina	85	(25)
LVEF (%)		45 ± 13

# TTSH SeQuent Please Registry

Baseline Clinical Characteristics	%
Smoking	55.2
Diabetes	48.8
Hypertension	80.1
Hyperlipidaemia	81.7
Prior MI	31.5
Prior PCI	42.8
Prior CABG	7.4

# TTSH SeQuent Please Registry

Indications for DEB	N	(%)
Small Vessel Disease ( $\leq 2.8\text{mm}$ )	190	(53.4)
Instent Restenosis	78	(22)
Bifurcation	20	(5.6)
De novo ( $> 2.8\text{mm}$ )	21	(5.9)
Others	47	(13.2)

# TTSH SeQuent Please Registry

## Instent ReStenosis

	N	(%)
Bare metal stent ISR	45	(58)
Drug eluting stent ISR	33	(42)

## Types of ISR (Mehran Classification)

Type I	41	(53)
Type II	21	(27)
Type III	5	(6)
Type IV	11	(14)

# TTSH SeQuent Please Registry

## Angiographic and Procedural Variables:


No. of vessel disease	N	(%)
Single vessel disease	75	(22)
Double vessel disease	118	(35)
Triple vessel disease	146	(43)
<b>Glycoprotein IIb/IIIa inhibitors</b>	228	(67)

# TTSH SeQuent Please Registry

Target Vessel for PCI	N	(%)
LAD	133	(37.0)
RCA	66	(18.5)
Circumflex	60	(17.0)
Others*	97	(27.5)

\* Others include side-branches, SVG and left main

# TTSH SeQuent Please Registry



Mean number of DEB  $1.25 \pm 0.5$

Mean size of DEB, mm  $2.6 \pm 0.6$

Length of DEB, mm  $24.6 \pm 12.1$



# TTSH SeQuent Please Registry

Clinical Outcomes (In-hospital)	N	(%)
<b>CVS mortality*</b>	<b>3</b>	<b>(0.9)</b>
<b>MI</b>	<b>0</b>	<b>(0)</b>
<b>TLR</b>	<b>0</b>	<b>(0)</b>
<b>Lesion thrombosis</b>	<b>0</b>	<b>(0)</b>

*\*3 deaths : AMI and cardiogenic shock*

# TTSH SeQuent Please Registry

Clinical Outcomes (9 month)	N = 195	(%)
CVS mortality*	0	(0)
MI	5	(2.5)
TLR	8	(4.1)
Lesion thrombosis	0	(0)

***Composite MACE at 9 months: 4.6% ( 9 patients)***

# CASE HIGHLIGHTS




Lumen restored  
and re-endothelialized

# DEB for NSTEMI




**F/40 Presented with** anginal chest pain, raised Troponin with no ECG changes




# Bifurcation lesion in Cx



# Tortuous OM1



# Scoreflex 1:1 ratio






**Post POBA**



# DEB for NSTEMI



**Positioning DEB (no mismatch)**



**SeQuent Please 2.5\*30mm**



# Final Result




FFR or LAD > 0.80

- Adequate predilatation
- Residual restenosis <30%
- Cutting balloon used
- Avoid geographic mismatch ie DEB always cover POBA'd segment
- Low pressure deployment of DEB at 8 atm
- 30s to 45s inflation time

# Tips

- Hybrid approach
- DES to proximal segment
- DEB to distal segment to ensure good outflow

# Novel Use of DEB




Ostial LAD lesion. Cardiogenic Shock

# CTO of RCA. On triple inotropes



# IABP plus NA, Dopamine and Dobutamine with SBP at 50mmHg Intermittent CPR




**2 long bare metal stents in left main-LAD  
3.5 x 28mm ; 3.0 x 18mm stents**




# Novel Use of DEB

- **Pt was critically ill and required IABP and triple inotropes with intermittent CPR**
- **Condition stabilised and improved**
- **Brought back to cath.lab 2 days later for relook angiogram + IVUS +/- stent optimisation**
- **IVUS showed underexpanded stents in left main and LAD**




**Stent optimisation with  
SP 3.5 x 30mm balloon**






**Stent optimisation with  
SP 4.0 x 20mm balloon**

# Novel Use of DEB





**Final angiogram**




**Well expanded stent**

# Routine restudy at 2 months prior to CTO RCA






# Diffuse LAD disease



# Occluded LAD and Cx




# Diseased RCA







# Collaterals to LAD



# LV function preserved





# How to treat this patient?

- Classical angina
- Poor target for CABG esp LAD
- 44 years old only
- Non diabetic
- Smoker

# PCI LAD

- RRA 6FS
- VL3.0 guide
- Whisper wire crossed with OTW support.
- 1.0 balloon eventually crossed the lesion with Guideliner support
- Aggressive predilation done with scoring balloon.






# After POBA and Scoring balloon



# Devices?

- SeQuent Please
  - 2.0 by 20mm
  - 8 atm
  - 45 s





# DEB in small distal vessels




Where no stent has gone before.....


# Bioabsorbable stents

**Absorb 2.5 by 28mm**



**Absorb 3.0 by 28mm**







# Final result



DEB

DEB Only

DEB + BMS

DEB + BVS

ISR

Small Vessels Disease  
Bifurcation

Dissection after  
DEB

Hybrid approach  
Reconstructing  
Diffusely  
diseased vessels

# There is Life after Bioabsorbable stent

## DEB

- Does not look for perfection
- 30% residual stenosis is acceptable
- Great promise in small vessel disease 2.0 to 2.5mm
- 1 months DAPT
- CE Mark since 2009
- IIa recommendation for ISR
- Strut?







## BVS

- Needs meticulous scaffold deployment
- OCT or IVUS
- Smallest stent size is 2.5mm
- Largest 3.5mm
- Minimum of 6 months DAPT
- CE Mark since 2011
- Only for de novel lesion
- 150  $\mu\text{m}$  strut thickness

# Strut and Coating Thickness In Perspective

*Thicker struts = larger stent profile and less deliverable*

**DEB?**

	Durable Polymer Coated Stents		Bioabsorbable Polymer Coated Stents			Bioabsorbable Stent	
	Xience V™/PROMUS™ Xience Prime™ TAXUS Element™ PROMUS Element™		Resolute Integrity™	BioMatrix Flex™	Nobori™	SYNERGY™	ABSORB™ BVS
							
Strut Thickness	<b>81 µm</b> (0.0032")	89 µm (0.0035")	120 µm (0.0047")	125 µm (0.0049")	74 µm (0.0029")	150 µm (0.0059")	
Polymer Coating Type & Thickness	Conformable 7-8µm / side	Conformable 6µm / side	Abluminal 11µm	Abluminal 20µm	Abluminal 3-4µm	Conformable 3µm / side	



# POBA vs DEB POBA


## Old Technology




## With a Modern Take





# Bifurcation and ISR







# LAD Bifurcation





Cx lesion




# 3.5 by 12mm Absorb Stent



# Predilated with 2.5x15mm




# DEB 2.5x17mm treating ISR at 10 atm








**ISR well expanded by ostial D1  
untidy**




# DEB 2.5 by 10mm to D1 ostium at 8 atm



# To stent or not to stent?




**DEB 3.0 by 10mm at 8 atm**  
**Avoid Geographical mismatch**



# LAO Cranial




# AP cranial



# Final result

Before



After DEB



# Final result

Before



After DEB

